2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6165 Building infrastructure for bispecific antibody therapy in community practice: Results from a protocol-driven quality improvement initiative

Tycel Phillips, MD, FASCO, Peter Riedell, MD2, Caron Jacobson, MD, MMSc3, Emily Zyborowicz, MPH4, Jeffrey Carter5, Chelsie Anderson Chadha6, Laura Simone, PhD7, Shelby Sullivan, PharmD8
1 City of Hope National Medical Center, Duarte, California, United States
2 University of Chicago, Chicago, Illinois, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 PRIME Education, New York, New York, United States
5 PRIME Education, New York, New York, United States
6 PRIME Education, New York, New York, United States
7 PRIME Education, New York, New York, United States
8 PRIME Education, New York, New York, United States

Background
As bispecific antibodies (bsAbs) are increasingly administered in outpatient settings for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), there is a critical need for standardized, evidence-based workflows to support patient identification, administration, care coordination, and adverse event (AE) management. This QI initiative aimed to develop, implement, and evaluate a multidisciplinary Bispecific Antibody Integration Protocol to operationalize and scale bsAb delivery in community oncology clinics.

Methods
Baseline surveys of community providers (N=114) assessed practice patterns, barriers, and preparedness related to bsAb therapy, while a multidisciplinary steering committee developed a standardized Bispecific Antibody Integration Protocol to guide evidence-based care processes. Team-based protocol integration sessions (pre-survey N=120, post-survey N=82) and refinement workshops (N=50) enabled ten participating clinics to identify operational gaps, optimize workflows, and develop clinic-specific action plans for implementation. Follow-up surveys completed by clinic champions (N=13) evaluated sustained integration of protocols and reported practice changes over time.

Results
Baseline: Gaps included lack of standardized protocols, limited preparedness, and inconsistent workflows for patient identification, bsAb delivery, and care coordination. On pre-session surveys, 51% of providers identified keeping up with evolving evidence as a key barrier to identifying eligible patients. Almost half of the providers reported low confidence in differentiating and administering bsAbs in the outpatient setting and only 56% of providers reported their clinic was prepared to manage bsAb-related AEs.

Protocol Integration Sessions: Participation improved knowledge of bsAb differentiation and competence in AE recognition. High/very high confidence in integration of educational resources and tools into clinic workflows to improve bsAb delivery and care increased from 46% to 72% post-activity. Teams developed action plans focused on protocolizing care, including creation of standardized order sets, step-up dosing workflows, cytokine release syndrome management pathways, and processes to improve coordinated care transitions.

Refinement Workshops: Ninety-five percent of providers reported high/very high confidence in employing multidisciplinary strategies for bsAb delivery, including patient identification, risk-mitigated administration, and AE management after participating in both activities. Notably, two clinics that had not previously administered bsAbs reported initiating outpatient bsAb delivery during the refinement phase, reflecting early adoption of newly developed workflows. Teams reported meaningful workflow changes, including standardized documentation of premedications and prior treatment cycles, improved multidisciplinary communication, and enhanced coordination with hospital partners. Persistent barriers included time and operational constraints.

Follow-Up: Sustained improvements were reported by clinic champions with 92% indicating high/very high confidence in identifying eligible patients and administering bsAb therapy with appropriate AE management. Additionally, 46% and 38% of clinic champions reported prescribing bsAbs more or much more often for patients with R/R DLBCL and FL, respectively, following participation in the initiative. Clinics also reported ongoing utilization of the Bispecific Antibody Integration Protocol to support patient identification, administration, and AE management.

Conclusions
This QI initiative demonstrates that a structured, protocol-driven, multidisciplinary approach can address key barriers to bsAb integration in community settings by enabling workflow standardization, improving patient identification, and strengthening care coordination. These changes were associated with improved provider confidence, competence, and increased adoption of bsAbs in R/R DLBCL and FL. Ongoing challenges related to evolving evidence and operational constraints highlight the need for sustained education and system-level support. These findings support the scalability of protocol-based strategies to optimize safe and effective bsAb delivery in community practice.

Study Sponsor Statement
The study reported was supported by an educational grant from Genmab US, Inc., who had no role in the study design, execution, analysis, or reporting.

Tycel Phillips, MD, FASCO: BMS - Research Funding; Abbvie - Research Funding; Genentech - Research Funding; Sobi - Research Funding; Abbvie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Astra Zeneca - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Caribou - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); J&J - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); Immunome - Consultancy (Includes expert testimony); ADCT - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BeOne Medicines, Ltd - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Xencor - Consultancy (Includes expert testimony)